KRAS and cancer: In addition, the study aimed at determining novel dependencies in GTPase KRas (KRAS–a signal transducer protein, which when mutated enhances tumor cell fitness) mutant cancer cells revealed that the mutant KRAS-driven pancreatic and colon cancer cell models were found to be more sensitive to CDK1 inhibition than KRAS wild-type cell lines in colony formation and cell survival experiments [186].